19. treatment of genetic diseases somatic cell gene therapy
Post on 20-Dec-2015
222 views
TRANSCRIPT
19. Treatment of Genetic Diseases
Somatic Cell Gene Therapy
a). Treatment strategiesi). Metabolic manipulationii). Manipulation of the proteiniii). Modification of the genome
b). Strategies for gene transfer
Three categories of somatic cell gene therapy:1. Ex vivo – cells removed from body, incubated with
vector and gene-engineered cells returned to body.2. In situ – vector is placed directly into the affected
tissues.3. In vivo – vector injected directly into the blood stream.
Example of ex vivo somatic cell gene therapy
• Usually done with blood cells because they are easiest to remove and return.
• Sickle cell anemia
Examples of in situ somatic cell gene therapy
• Infusion of adenoviral vectors into the trachea and bronchi of cystic fibrosis patients.
• Injection of a tumor mass with a vector carrying the gene for a cytokine or toxin.
• Injection of a dystrophin gene directly into the muscle of muscular dystrophy patients.
Example of in vivo somatic cell gene therapy
• No clinical examples.
• In vivo injectable vectors must be developed.
Barriers to successful gene therapy:1. Vector development2. Corrective gene construct3. Proliferation and maintenance of target cells4. Efficient transfection and transport of DNA to nucleus for
integration into genome 5. Expansion of engineered cells and implantation into patient
Types of vectors• RNA viruses (Retroviruses)
1. Murine leukemia virus (MuLV)2. Human immunodeficiency viruses (HIV)3. Human T-cell lymphotropic viruses (HTLV)
• DNA viruses1. Adenoviruses2. Adeno-associated viruses (AAV)3. Herpes simplex virus (HSV)4. Pox viruses5. Foamy viruses
• Non-viral vectors1. Liposomes2. Naked DNA3. Liposome-polycation complexes4. Peptide delivery systems
Advantages:1. Randomly integrates into genome2. Wide host range3. Long term expression of transgeneDisadvantages:1. Capacity to carry therapeutic genes is small2. Infectivity limited to dividing cells3. Inactivated by complement cascade4. Safety
Adenovirus Advantages:
1. Efficiency of transduction is high
2. High level gene expression
3. Slightly increased capacity for exogenous DNA
Disadvantages:
1. Expression may be transient
2. Cell-specific targeting difficult to achieve
3. Virus uptake is ubiquitous
4. Safety
Other viral vectors
• Adeno-associated virus – infects wide range of cells (both dividing and non-dividing), able to integrate into host genome, not associated with any human disease, high efficiency of transduction.
• Herpes simplex virus, vaccinia virus, syndbis virus, foamy viruses – not yet widely studied
• Onyx virus – limited replicating adenovirus that replicates mainly in tumor cells.
1. Liposome 2. Cationic polymers
Non-viral vectors
May overcome limitations with viruses including small capacity for therapeutic DNA, difficulty in cell-type targeting and safety concerns.
4. Peptide-mediated gene delivery
3. Naked DNA
Synthesis of a retroviral gene therapy vector
Site of insertion of therapeutic gene
Selectable marker for transduced cells
Percent effort directed towards different gene therapy trials.
Examples of Gene Therapy Trials
• Adenosine deaminase gene transfer to treat Severe Combined Immuno-Deficiency (SCID)
• CFTR gene transfer to treat Cystic Fibrosis (CF)• Advanced Central Nervous System (CNS)
Malignancy• Mesothelioma• Ornithine Transcarbamylase Deficiency• Hemophilia• Sickle Cell DiseaseSickle Cell Disease
Stem Cell Transplantation
Harvest marrow
Radiation/Chemotherapy
Infuse normal donor cells
Donor
Patient
Stem Cell Gene Therapy
Harvest marrow
Introduce therapeutic gene
Radiation/Chemotherapy
Reinfuse corrected cells
Make genePut into vehiclefor delivery into cell
The Molecular Basis of Sickle Cell Anemia
2
1
s
LCR
s chains
chains
2 s2
Polymerization
Survives 15 - 25 daysSickled red cell
120 days
Sickle Cell
Normal
Preferential Survival of Normal Red Blood Cells
in Sickle Cell Anemia
20 days
Gene Therapy for Sickle Cell Anemia
2
1
s
LCR
s chains
chains
2 s
chains
Non-sickled red cellSurvives 120 days
No polymerization
LCR
Mixed Chimerism following BMT for Thalassemia and Sickle Cell
Disease• Occurs in a minority of patients (5 - 10%).• A minority of donor-origin progenitors (10 -
20%) is sufficient to ameliorate disease.
Thus, it may be possible to achieve therapeutic effects by gene transfer into only a fraction of stem cells.
Preferential Survival of Normal Red Blood Cells
20 / 120 = 1/6thnormal or corrected stem cells
= 50% corrected mature red cells
TURNOVERRATE
LOW
HIGH
Therapeutic effects from small numbers of normal
stem and progenitor cells in the marrow
BONE MARROW BLOOD
120 days
SSSSSS
N
20 days
Approaches to Improving the Efficiency of Gene Therapy Targeting
the Stem Cell
• Use selection to exponentially expand stem cells carrying the therapeutic gene.
• Use repeated treatments to additively expand stem cells carrying the therapeutic gene.
In Vivo Selection
Selectable gene =MDR1 (taxol, navelbine, vinblastine)DHFR (methotrexate)Other (MGMT, aldehyde dehydrogenase,
cytidine deaminase)
Therapeutic gene Selectable gene
In Vivo Selection of Genetically Modified Bone Marrow
Drug Treatment
Gene Therapy for Sickle Cell Disease
REPEAT In vivo selection
GCSF
MobilizeStem Cells
Introduce gene Re-infuse
One developing technology that may be utilized for gene therapy is nuclear transfer (“cloning”).
What’s in a Name? – Nuclear Transplantation vs. Therapeutic Cloning vs. Human
Reproductive Cloning.
Ethical Considerations
• Use of technology for non-disease conditions such as functional enhancement or “cosmetic” purposes – for example, treatment of baldness by gene transfer into follicle cells , larger size from growth hormone gene, increased muscle mass from dystrophin gene.
• In utero somatic gene therapy – only serious disease should be targeted and risk-benefit ratios for mother and fetus should be favorable.
• Potential for real abuse exists by combining human reproductive cloning and genetic engineering.